Skip to content
Business Company News, Finance Investment

House Economics Committee to test ideas with the ACCC, NCC, Treasury, and the Productivity Commission

Department of the House of Representatives < 1 mins read

The House of Representatives Standing Committee on Economics will be rounding out its inquiry into promoting economic dynamism, competition and business formation with its next public hearing on 15 September 2023. The Australian Competition and Consumer Commission (ACCC), National Competition Council (NCC), Treasury and the Productivity Commission will be appearing.

Committee chair Dr Daniel Mulino MP said that the public hearing will allow the committee to test ideas with experts from the ACCC, NCC, Treasury and the Productivity Commission.

“The committee has heard a range of ideas and recommendations about how to boost healthy competition and productivity throughout this inquiry. The ACCC, NCC, Treasury and the Productivity Commission are key players in this area, so the committee will benefit from hearing their perspectives and testing ideas with them.”

The committee will also hear from Meta, which will complete the Committee’s engagement with big tech. The committee has previously heard from Apple, Google and Amazon.

More details about the inquiry, including the full terms of reference, are available on the committee’s website.

Public hearing details

Date: Friday, 15 September 2023
Time: 8.00am – 5.00pm
Location: Videoconference

The hearing will be broadcast live at aph.gov.au/live.

Media inquiries

Dr Daniel Mulino MP
Electorate: (03) 9070 1974
Parliament: (02) 6277 4311

For background information

Committee Secretariat
02 6277 4587
[email protected]
www.aph.gov.au/economics

More from this category

  • Biotechnology, Business Company News
  • 10/12/2025
  • 10:17
Jane Morgan Management

TGA Provides Regulatory Clearance for LTR Pharma’s SPONTANĀ® Phase II Clinical Study

10 December 2025 – Brisbane, Australia |LTR Pharma Limited (ASX:LTP) has today announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) to commence its clinical trial activities for a Phase II clinical study for its nasal erectile dysfunction treatment SPONTAN®. This follows confirmation and acceptance of the Company’s Clinical Trial Notification (CTN). This regulatory clearance completes all requirements for study initiation in Australia and follows recent Human Research Ethics Committee (HREC) approval granted by Bellberry announced previously. LTR Pharma Executive Chairman, Lee Rodne, said: "The TGA’s regulatory clearance of our CTN represents an important milestone that…

  • Contains:
  • Business Company News, Finance Investment
  • 10/12/2025
  • 10:03
Hnry

Fintech Hnry Raises $30m to Accelerate Push into Australia and the UK

Key Facts: Hnry raises $30 million in fresh capital. Hnry will use the funds to grow its Australian and UK markets. Movac’s Growth Fund…

  • Contains:
  • Business Company News, General News
  • 10/12/2025
  • 08:00
Jirsch Sutherland

Festive spending warning: Aussies urged to act now

Key Facts: Australians risk significant post-Christmas debt with household spending up 5% year-on-year and savings ratios down to 4-5% Household costs have increased across…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.